Destiny Is Fulfilled in MapleStory’s Gigantic Two-Part Summer Update Destiny: Remastered and Destiny: Homecoming
MapleStory, Nexon’s original free-to-play, side scrolling 2D MMORPG with an aggressively cute game style, announces the first of its two-part summer update, “Destiny: Remastered,” lands in-game on June 15, filled to the brim with special events, a revamp of all of Explorer jobs, plus a gift package for pre-registering before June 13!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005606/en/
Nexon MapleStory Destiny: Remastered (Graphic: Business Wire)
SPECIAL EVENTS
Summer just wouldn’t be summer in MapleStory without some special, in-game events! It’s time for the season of music and majesty, as new friend Stella comes to experience Maple World first hand. There are a wealth of rewards to collect during the musical summer nights of Starlight Symphony, plus the return of Tera Burning Plus and Burning World. On top of all that, pre-register a character (must be level 61 or above) before 11am PDT on June 13 to get a special Destiny gift package featuring Lil Symphony pets, Angelic Alphabet Damage Skin, a heap of Melody Coins to get a head start in Starlight Symphony, and a Magician of the Sacred Forest outfit!
EXPLORER REVAMP
The Explorer class of characters in MapleStory has been the backbone of the game for the last seventeen years. These 14 unique Explorer jobs are receiving a complete overhaul of animations, improved skills, new story segments, and more.
The Explorer revamp benefits the following characters:
- Warrior: Hero, Paladin, Dark Knight
- Magician: Arch Mage (Fire/Poison), Arch Mage (Ice/Lightning), Bishop
- Bowman: Bowmaster, Marksman
- Thief: Night Lord, Shadower, Dual Blade
- Pirate: Corsair, Buccaneer, Cannoneer
IMPROVEMENTS GALORE
Incorporated into the “Destiny: Remastered” update are additional improvements, new boss accessories, and boss difficulties so everyone can enjoy a better Maple experience:
- No more Mastery Books! - Mastery Books are no longer needed to upgrade 4th Job skills.
- Dawn Boss Accessories set - Claim a new set of accessories from bosses to forge a powerful new set.
- New Boss Difficulties - Take on Chosen Seren and Verus Hilla on normal mode and overcome Will on easy difficulty.
BEAN BRIGADE “DESTINY: REMASTERED” SNEAK PEEK
Members of MapleStory’s content creator program, Bean Brigade, will be jumping into the test servers early beginning today to give Maplers a sneak peek of all the exciting changes and updates coming to “Destiny: Remastered.” Follow along on Bean Brigade’s dedicated Twitch page from June 7 through 10.
SUMMER UPDATE PART TWO
Last but not least, Summer Update Part Two, “Destiny: Homecoming,” arrives on July 20 with an all-new homestead feature allowing Maplers to purchase and decorate their very own home! Show off your exquisite taste and home decorating style, and be the envy of every other homeowner in Maple World. Also in Part Two, the Watcher Kalos awaits on top of Karote, the Unending Tower. Win in the battle against this formidable boss to obtain a new Eternal Equipment Set!
Grab your sunscreen and check out everything there is to do in MapleStory this summer!
Assets: HERE
Social Media:Twitch / Facebook / Twitter / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 17 years ago. There have been over 274 million characters created to date, which would make MapleStory’s Maple World the 4th highest populated country in the world.
About Nexon America Inc.https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005606/en/
Contact information
Brian Klotz
Nexon America
NA_pr@nexon.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom